{"id":103353,"date":"2025-04-09T09:11:47","date_gmt":"2025-04-09T07:11:47","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/"},"modified":"2025-10-13T14:57:40","modified_gmt":"2025-10-13T12:57:40","slug":"accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/","title":{"rendered":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02"},"content":{"rendered":"<p><strong>The biotechnology company <a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/accure-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Accure Therapeutics<\/a>, focused on developing innovative treatments for central nervous system disorders, has announced it has received \u20ac1.48 million in grants awarded by The Michael J. Fox Foundation (MJFF) and the Luxembourg National Research Fund (FNR). The funding will support the advancement of its drug candidate ACT-02 for Parkinson&#8217;s disease. Headquartered at the Barcelona Science Park, the company expects to reach the clinical stage by the end of 2026.<\/strong><\/p>\n<p>The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02\u2014an innovative compound with potential disease-modifying properties. ACT-02 functions as an inhibitor of prolyl endopeptidase, a promising therapeutic target that has remained largely unexplored to date. The program is currently in an advanced preclinical stage, supported by positive efficacy results in vivo models of Parkinson\u2019s disease, as well as favorable safety and toxicology data generated under GLP (Good Laboratory Practice) standards.<\/p>\n<p>Accure Therapeutics has received a \u20ac1 million grant from The Michael J. Fox Foundation, which will be used to complete the preclinical activities required to finalize the Investigational New Drug (IND) studies, with the aim of submitting a request for entry into the Phase I clinical trial in 2026. This project is being carried out in collaboration with the Institute of Pharmacology, Toxicology, and Pharmacy at the Stiftung Tier\u00e4rztliche Hochschule Hannover.<\/p>\n<p>Meanwhile, the FNR BRIDGES program, managed by the Luxembourg National Research Fund (FNR), has provided \u20ac480,000 in funding to support the evaluation of ACT-02\u2019s efficacy in highly translational Parkinson\u2019s disease models using patient-derived induced pluripotent stem cells (iPSCs). The goal is to enhance patient selection and stratification for future precision medicine strategies.<\/p>\n<p>&#8220;We are grateful to The Michael J. Fox Foundation and the Luxembourg National Research Fund for their financial support of our asset ACT-02 as a potential therapy for people with Parkinson\u2019s disease. These two grants represent significant steps forward for us and our academic partners in developing our first-in-class drug candidate, ACT-02, for Parkinson\u2019s disease,&#8221; says <strong>Laurent Nguyen<\/strong>, co-founder and CEO of Accure Therapeutics. &#8220;Following in the footsteps of ACT-01, our first neuroprotective program that recently achieved positive results in the Phase II clinical trial in neuro-ophthalmology, our goal with ACT-02 is to develop a game-changing drug,&#8221; Nguyen adds.<\/p>\n<p><a href=\"https:\/\/accure.health\/accure-therapeutics-awarded-a-total-of-1-6m-in-grants-from-the-michael-j-fox-foundation-and-fonds-national-de-recherche-de-luxembourg-to-bring-first-in-class-drug-for-parkinsons-disease-t\/\" target=\"_blank\" rel=\"noopener\"><strong>\u00bb More information [+]<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The biotechnology company Accure Therapeutics, focused on developing innovative treatments for central nervous system disorders, has announced it has received \u20ac1.48 million in grants awarded by The Michael J. Fox&#8230;<\/p>\n","protected":false},"author":1,"featured_media":103367,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[35],"tags":[297],"class_list":["post-103353","post","type-post","status-publish","format-standard","has-post-thumbnail","category-business","tag-accure-therapeutics-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"description\" content=\"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-09T07:11:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T12:57:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"330\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"adminpcb\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminpcb\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/\"},\"author\":{\"name\":\"adminpcb\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"headline\":\"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02\",\"datePublished\":\"2025-04-09T07:11:47+00:00\",\"dateModified\":\"2025-10-13T12:57:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/\"},\"wordCount\":386,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"keywords\":[\"Accure Therapeutics\"],\"articleSection\":[\"COMPANIES\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/\",\"name\":\"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"datePublished\":\"2025-04-09T07:11:47+00:00\",\"dateModified\":\"2025-10-13T12:57:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\"},\"description\":\"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2025\\\/04\\\/Adobe-Express-file-3.png\",\"width\":900,\"height\":330},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/d13cab05cd0a75b17fddca8496481021\",\"name\":\"adminpcb\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g\",\"caption\":\"adminpcb\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/adminpcb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona","description":"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/","og_locale":"en_US","og_type":"article","og_title":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona","og_description":"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.","og_url":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2025-04-09T07:11:47+00:00","article_modified_time":"2025-10-13T12:57:40+00:00","og_image":[{"width":900,"height":330,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","type":"image\/png"}],"author":"adminpcb","twitter_card":"summary_large_image","twitter_misc":{"Written by":"adminpcb","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/"},"author":{"name":"adminpcb","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"headline":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02","datePublished":"2025-04-09T07:11:47+00:00","dateModified":"2025-10-13T12:57:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/"},"wordCount":386,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","keywords":["Accure Therapeutics"],"articleSection":["COMPANIES"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/","url":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/","name":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02 - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","datePublished":"2025-04-09T07:11:47+00:00","dateModified":"2025-10-13T12:57:40+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021"},"description":"The funding will drive two preclinical development programs for its groundbreaking drug, ACT-02 with potential disease-modifying properties.","breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2025\/04\/Adobe-Express-file-3.png","width":900,"height":330},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/accure-therapeutics-obtains-e1-5-million-in-grants-to-accelerate-development-of-its-parkinsons-drug-act-02\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Accure Therapeutics Obtains \u20ac1.5 Million in Grants to Accelerate Development of Its Parkinson\u2019s Drug ACT-02"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/d13cab05cd0a75b17fddca8496481021","name":"adminpcb","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/41ad0fab4bb3bf5348b0af9612159cfd93173a57bbca98fecb50fa6f3ab97d28?s=96&d=mm&r=g","caption":"adminpcb"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/adminpcb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103353","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=103353"}],"version-history":[{"count":3,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103353\/revisions"}],"predecessor-version":[{"id":103466,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/103353\/revisions\/103466"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/103367"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=103353"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=103353"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=103353"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}